GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK plc has announced the purchase of 494,426 of its own ordinary shares as part of ...

The FTSE 100 began Friday’s session on a positive note, gaining 23 points, reaching 9,124, as investors paid attention to ...

GlaxoSmithKline Pharmaceuticals' shares fell by 2% in Thursday's morning trade, reflecting a bearish market sentiment. The company is currently trading at Rs 2,680.10 per share.

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...